Trials / Completed
CompletedNCT02477488
Optimal Administration of Allopurinol in Dialysis Patients
Optimal Administration of Allopurinol in Dialysis Patients : A Chronotherapy Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Maisonneuve-Rosemont Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Gout has a strong association with the metabolic syndrome, and it is often seen in patients with renal insufficiency. Allopurinol is a medication intended to lower uric acid and therefore prevents gout attacks. Its metabolism is mainly renal, and some evidence shows that it is also dialyzable. The hypothesis is that allopurinol would be more efficacious to lower uric acid if it was given after dialysis only. The investigators will then switch administration of allopurinol to bedtime for dialysis patients currently taking that medication.
Detailed description
Gout has a strong association with the metabolic syndrome, and it is often seen in patients with renal insufficiency. A study has shown an incidence of fifteen percent of gout in the first five years spent in dialysis and it was associated with an increased mortality. Allopurinol is a medication intended to lower uric acid and therefore prevents gout attacks. Its metabolism is mainly renal, and some studies from the early 1960s demonstrated that it is also dialyzable. At the moment, we do not have strong evidence of the optimal dosage of allopurinol with modern techniques of dialysis. The hypothesis is that allopurinol would be more efficacious to lower uric acid if it was given after dialysis only. The investigators will then switch administration of allopurinol to bedtime for dialysis patients currently taking that medication. Dosage of uric acid will be performed to assess the efficacy of the intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Allopurinol | Administration of allopurinol is changed to bedtime (hs) for each patient, at the same dosage as was previously prescribed. |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2015-06-22
- Last updated
- 2016-09-13
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02477488. Inclusion in this directory is not an endorsement.